Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...
BMO Capital analyst Evan Seigerman upgraded Replimune (REPL) to Market Perform from Underperform with a price target of $11, up from $2. The firm ...
Millions of Python developers using Visual Studio Code find updated data science functionality in the new release of version 1.94, the September 2024 edition of Microsoft's open-source-based editor.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback